Research projects
Start of main content
Novel immunotherapeutic strategies against T-ALL, a rare pediatric disease
19th national competition for scientific and technical research
Rare diseases

Senior Researcher : María Luisa Toribio García
Research Centre or Institution : Centro de Biología Molecular "Severo Ochoa". CSIC-Universidad Autónoma de Madrid
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive, hematological disease arising duringT-lymphocyte development, representing 10-15% of pediatric ALLs. T-ALL is still characterized by high relapse rates and ineffective options for refractory disease, resulting in poor clinical outcomes. Consequently, development of novel and more effective therapeutic strategies is an urgent unmet need. The development of T-cells expressing a Chimeric Antigen Receptor (CAR) to specifically recognize and attack the patient’s tumoral cells has revolutionized B-cell leukemia treatment. However, the sharing of cell-surface molecules by normal and tumoral T-cells posed a challenge to develop CAR T-cell therapies for this disease. We here propose to circumvent current limitations by implementing an innovative CAR T-cell therapy targeting a molecule specifically expressed in T-ALL cells but absent in normal T cells. Our preliminary results supported the hypothesis that pre-TCR, a molecular complex expressed in developing immature T cells may be a suitable T-ALL-specific target for CAR-T therapy.
Based on this hypothesis, we approached the following specific aims:
1. Defining the functional relevance of pre-TCR as a T-ALL biomarker.
2. Developing pre-TCR-CAR-engineered T cells and validating their function in vitro.
3. Preclinically validating in vivo T-ALL-targeted immunotherapy using pre-TCR-specific CAR-T cells.
The results obtained are as follows:
1. We have demonstrated that pre-TCR is a biomarker of T-ALL leukemia initiating cells, which is required for leukemia generation, maintenance and progression, supporting that pre-TCR is an optimal T-ALL therapeutic target.
2. We have produced pre-TCR-specific 2nd-generation (4-1BB, CD3z) primary human CAR-T cells that have been functionally validated against pre-TCR+ T-ALLs in vitro.
3. We showed that in vivo administration of pre-TCR-CAR-T cells hampers T-ALL progression and increases overall mouse survival in preclinical T-ALL models, providing formal proof of the therapeutic efficacy of pre-TCR-specific CAR-T cells as a novel immunotherapy to improve life expectancy of T-ALL patients.
Scientific Production |
|
---|---|
Magazine Articles | 2 |
Communications at national conferences | 5 |
Communications at international conferences | 4 |
-
Activities related
-
Projects related
-
News related
-
Publications related
-
4
Jun
2019
International Symposium Genomic Medicine Madrid, Tuesday and Wednesday, June 4 and 5, 2019 9:30 hours
-
27
Nov
2019
International Symposium Undiagnosed and rare diseases in children and adolescents: Translation to clinic and society Barcelona, Wednesday and Thursday, November 27 and 28, 2019 9:30 hours
-
30
Jan
2020
International Symposium Understanding and reprogramming developmental visual disorders: from anophthalmia to cortical impairments Madrid, Thursday and Friday, 30 and 31 January 2020, 9:30 hours
- Systemic analysis of the gene regulatory networks involved in the specification and maintenance of the retinal pigment epithelium: towards new therapies for retinal degenerative diseases 2016 Senior Researcher : Paola Bovolenta Nicolao Research Centre or Institution : Centro de Biología Molecular "Severo Ochoa". CSIC-Universidad Autónoma de Madrid
- Molecular basis of immune deficiency in Wolf-Hirschhorn Syndrome (4p-) 2016 Senior Researcher : César Cobaleda Hernández Research Centre or Institution : Centro de Biología Molecular "Severo Ochoa". CSIC-Universidad Autónoma de Madrid
- AGC1 deficiency and calcium signaling in mitochondria: a new disease model for the study of pathogenic mechanisms and for the development of therapeutic strategies 2016 Senior Researcher : Jorgina Satrústegui Gil-Delgado Research Centre or Institution : Centro de Biología Molecular "Severo Ochoa". CSIC-Universidad Autónoma de Madrid
-
-
Expertos piden ampliar la prueba del talón a más enfermedades
Published on 01/15/2019
End of main content